Can‑Fite BioPharma Ltd. announced that its orally bioavailable A3 adenosine receptor agonist, Namodenoson, met the primary safety endpoint in a 20‑patient, open‑label Phase 2a study of advanced pancreatic ductal adenocarcinoma patients who had progressed after prior systemic therapy. The study, conducted in Ramat Gan, Israel, found no new safety signals and confirmed the drug’s favorable safety profile in a heavily pre‑treated, high‑risk population.
Secondary analyses revealed that one‑third of patients were alive at the data cut‑off, and overall survival and progression‑free survival data are still maturing. The safety success, combined with early survival signals, supports continued clinical development and reinforces the company’s strategy to advance its A3AR platform across multiple solid tumor indications. Namodenoson has also received Orphan Drug Designation from the U.S. Food and Drug Administration for pancreatic cancer, providing regulatory incentives that could accelerate future approval pathways.
Despite the clinical progress, Can‑Fite remains in a precarious financial position. For the fiscal year 2024, the company reported an operating margin of –1,206.2 % and a net margin of –1,571.2 %. Revenue declined 9.3 % year‑over‑year to $674 k for the trailing twelve months ending June 30, 2025, and the Altman Z‑Score stands at –26.39, indicating significant financial distress. These figures underscore that while the safety milestone is encouraging, the company’s ability to fund further development and achieve commercial viability remains uncertain.
Professor Salomon Stemmer, oncologist at the Davidoff Center, Rabin Medical Center, Israel, noted that “the favorable safety profile observed in this difficult‑to‑treat population supports continued clinical evaluation of namodenoson.” Chief Scientific Officer Pnina Fishman added that “with enrollment now complete and safety continuing to be favorable, we believe we are well positioned to generate meaningful efficacy top‑line data in Q3 2026.”
The announcement was met with a strong positive market reaction, reflecting investor optimism about the drug’s safety profile and potential survival benefit. The company plans to release top‑line efficacy data in the third quarter of 2026 and will continue to pursue development of Namodenoson in other indications, including advanced liver cancer and metabolic dysfunction‑associated steatohepatitis.
The next steps for Can‑Fite include monitoring the maturation of survival data, preparing for the upcoming efficacy report, and exploring partnership or funding opportunities to support the continued development of its A3AR platform. The company’s financial challenges will remain a key consideration for investors as they assess the long‑term viability of the pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.